SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001213900-20-002280
Filing Date
2020-01-31
Accepted
2020-01-31 16:31:35
Documents
5
Period of Report
2018-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO FORM 20-F f20f2018a2_enlivextherap.htm 20-F/A 68564
2 CERTIFICATION f20f2018a2ex12-1_enlivex.htm EX-12.1 7238
3 CERTIFICATION f20f2018a2ex12-2_enlivex.htm EX-12.2 6718
4 CERTIFICATION f20f2018a2ex13-1_enlivex.htm EX-13.1 3672
5 CERTIFICATION f20f2018a2ex13-2_enlivex.htm EX-13.2 3671
  Complete submission text file 0001213900-20-002280.txt   91109
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-36578 | Film No.: 20565491
SIC: 2834 Pharmaceutical Preparations